Cabeza, LauraOrtiz, RaúlArias, José LPrados, JoseRuiz Martínez, Maria AdolfinaEntrena, José MLuque, RaquelMelguizo, Consolación2015-12-022015-12-022015-02-13Cabeza L, Ortiz R, Arias JL, Prados J, Ruiz Martínez MA, Entrena JM, et al. Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles. Int J Nanomedicine. 2015; 10:1291-3061176-9114http://hdl.handle.net/10668/2099Journal Article; Research Support, Non-U.S. Gov't;The use of doxorubicin (DOX), one of the most effective antitumor molecules in the treatment of metastatic breast cancer, is limited by its low tumor selectivity and its severe side effects. Colloidal carriers based on biodegradable poly(butylcyanoacrylate) nanoparticles (PBCA NPs) may enhance DOX antitumor activity against breast cancer cells, thus allowing a reduction of the effective dose required for antitumor activity and consequently the level of associated toxicity. DOX loading onto PBCA NPs was investigated in this work via both drug entrapment and surface adsorption. Cytotoxicity assays with DOX-loaded NPs were performed in vitro using breast tumor cell lines (MCF-7 human and E0771 mouse cancer cells), and in vivo evaluating antitumor activity in immunocompetent C57BL/6 mice. The entrapment method yielded greater drug loading values and a controlled drug release profile. Neither in vitro nor in vivo cytotoxicity was observed for blank NPs. The 50% inhibitory concentration (IC50) of DOX-loaded PBCA NPs was significantly lower for MCF-7 and E0771 cancer cells (4 and 15 times, respectively) compared with free DOX. Furthermore, DOX-loaded PBCA NPs produced a tumor growth inhibition that was 40% greater than that observed with free DOX, thus reducing DOX toxicity during treatment. These results suggest that DOX-loaded PBCA NPs have great potential for improving the efficacy of DOX therapy against advanced breast cancers.enBiodegradable polymerCarcinomaCytotoxicityChemotherapeutic drugDrug deliveryNanopolymerAdsorciónAnimalesNeoplasias de la mamaLínea celular tumoralCianoacrilatosPreparaciones de acción retardadaDoxorrubicinaEnbucrilatoHumanosConcentración 50 inhibidoraRatones consanguíneos C57BLNanopartículasMedical Subject Headings::Phenomena and Processes::Chemical Phenomena::Physicochemical Phenomena::Physicochemical Processes::AdsorptionMedical Subject Headings::Organisms::Eukaryota::AnimalsMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Breast NeoplasmsMedical Subject Headings::Anatomy::Cells::Cells, Cultured::Cell Line::Cell Line, TumorMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Acyclic::Acrylates::CyanoacrylatesMedical Subject Headings::Chemicals and Drugs::Pharmaceutical Preparations::Dosage Forms::Delayed-Action PreparationsMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Polycyclic Hydrocarbons, Aromatic::Naphthacenes::Anthracyclines::Daunorubicin::DoxorubicinMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Acyclic::Acrylates::Cyanoacrylates::EnbucrilateMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Toxicity Tests::Inhibitory Concentration 50Medical Subject Headings::Organisms::Eukaryota::Animals::Animal Population Groups::Animals, Inbred Strains::Mice, Inbred Strains::Mice, Inbred C57BLMedical Subject Headings::Technology, Industry, Agriculture::Technology, Industry, and Agriculture::Manufactured Materials::Nanostructures::Nanoparticlesresearch article25709449open access10.2147/IJN.S743781178-2013PMC4335619